Drugs / Trastuzumab Rezatecan
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07581574 | May 2026 → May 2027 expected | gastroesophageal adenocarcinoma | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trastuzumab Rezatecan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07581574 ↗ |
| Route | Intravenous | “Trastuzumab Rezatecan（Dosage: 4.8 mg/kg, intravenous infusion；Frequency: Once every 3 weeks (Q3W)）” NCT07581574 ↗ |